AR107547A1 - Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso - Google Patents
Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su usoInfo
- Publication number
- AR107547A1 AR107547A1 ARP170100296A ARP170100296A AR107547A1 AR 107547 A1 AR107547 A1 AR 107547A1 AR P170100296 A ARP170100296 A AR P170100296A AR P170100296 A ARP170100296 A AR P170100296A AR 107547 A1 AR107547 A1 AR 107547A1
- Authority
- AR
- Argentina
- Prior art keywords
- maleate
- preparation processes
- crystal forms
- tlr7 agonist
- crystalline form
- Prior art date
Links
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title abstract 3
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere a un maleato del compuesto de fórmula (1), el proceso de preparación de la sal, la composición farmacéutica que contiene la sal y su uso. Además se refiere a la forma cristalina C, la forma cristalina D y la forma cristalina E del maleato del compuesto de fórmula (1); a sus procesos de preparación, composiciones cristalinas y composiciones farmacéuticas que las contienen, y a su uso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082030.0A CN107043380A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107547A1 true AR107547A1 (es) | 2018-05-09 |
Family
ID=59500111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100296A AR107547A1 (es) | 2016-02-05 | 2017-02-06 | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10780091B2 (es) |
| EP (1) | EP3412671B1 (es) |
| JP (1) | JP6898336B2 (es) |
| KR (1) | KR102393279B1 (es) |
| CN (2) | CN107043380A (es) |
| AR (1) | AR107547A1 (es) |
| AU (1) | AU2017215800B2 (es) |
| CA (1) | CA3013682C (es) |
| CL (1) | CL2018002089A1 (es) |
| DK (1) | DK3412671T3 (es) |
| EA (1) | EA038794B1 (es) |
| ES (1) | ES2834303T3 (es) |
| HU (1) | HUE052211T2 (es) |
| IL (1) | IL260965B (es) |
| MX (1) | MX374295B (es) |
| MY (1) | MY196762A (es) |
| NZ (1) | NZ745231A (es) |
| PH (1) | PH12018501644B1 (es) |
| SG (1) | SG11201806682TA (es) |
| TW (1) | TWI778951B (es) |
| UA (1) | UA123781C2 (es) |
| WO (1) | WO2017133683A1 (es) |
| ZA (1) | ZA201805185B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| WO2019223788A1 (zh) * | 2018-05-25 | 2019-11-28 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| BR112021015577A8 (pt) | 2019-02-08 | 2021-10-05 | Research & Business Found Sungkyunkwan Univ | Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo |
| US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| JP7690222B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| EP0882727B9 (en) | 1996-07-03 | 2005-06-15 | Sumitomo Pharmaceuticals Company, Limited | Novel purine derivatives |
| JP4375901B2 (ja) | 1997-11-28 | 2009-12-02 | 大日本住友製薬株式会社 | 新規な複素環化合物 |
| CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| ES2541434T3 (es) | 2007-06-29 | 2015-07-20 | Gilead Sciences, Inc. | Derivados de purina y su uso como moduladores del receptor de tipo Toll 7 |
| ES2359123T3 (es) | 2007-08-03 | 2011-05-18 | Pfizer Limited | Imidazopiridinonas. |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| EP2670244B1 (en) | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| TR201807076T4 (tr) | 2012-10-10 | 2018-06-21 | Janssen Sciences Ireland Uc | Viral enfeksiyonların ve diğer hastalıkların tedavisine yönelik pirolo[3,2-d]pirimidin derivatları. |
| EP2922547B1 (en) | 2012-11-20 | 2017-03-08 | Glaxosmithkline LLC | Novel compounds |
| HRP20171150T1 (hr) | 2012-11-20 | 2017-10-06 | Glaxosmithkline Llc | Novi spojevi |
| EP2922550B1 (en) * | 2012-11-20 | 2017-04-19 | Glaxosmithkline LLC | Novel compounds |
| CA2938476A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
| NZ724878A (en) * | 2014-05-01 | 2019-03-29 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
| ES2877050T3 (es) * | 2014-05-01 | 2021-11-16 | Novartis Ag | Compuestos y composiciones como agonistas del receptor 7 de tipo toll |
| CN106661034B (zh) * | 2014-08-15 | 2019-11-29 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| TWI714661B (zh) | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| KR102112192B1 (ko) | 2015-11-05 | 2020-05-19 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Tlr7 효능제로서의 7-(티아졸-5-일)피롤로피리미딘 화합물 |
| CA3002299A1 (en) | 2015-11-05 | 2017-05-11 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043377A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043378A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
-
2016
- 2016-02-05 CN CN201610082030.0A patent/CN107043380A/zh active Pending
-
2017
- 2017-02-03 TW TW106103694A patent/TWI778951B/zh active
- 2017-02-04 PH PH1/2018/501644A patent/PH12018501644B1/en unknown
- 2017-02-04 ES ES17747003T patent/ES2834303T3/es active Active
- 2017-02-04 MX MX2018009500A patent/MX374295B/es active IP Right Grant
- 2017-02-04 JP JP2018540750A patent/JP6898336B2/ja active Active
- 2017-02-04 NZ NZ745231A patent/NZ745231A/en unknown
- 2017-02-04 EA EA201891770A patent/EA038794B1/ru unknown
- 2017-02-04 WO PCT/CN2017/072890 patent/WO2017133683A1/zh not_active Ceased
- 2017-02-04 HU HUE17747003A patent/HUE052211T2/hu unknown
- 2017-02-04 MY MYPI2018702706A patent/MY196762A/en unknown
- 2017-02-04 CN CN201780009746.0A patent/CN108602830B/zh active Active
- 2017-02-04 SG SG11201806682TA patent/SG11201806682TA/en unknown
- 2017-02-04 KR KR1020187024626A patent/KR102393279B1/ko active Active
- 2017-02-04 EP EP17747003.6A patent/EP3412671B1/en active Active
- 2017-02-04 AU AU2017215800A patent/AU2017215800B2/en active Active
- 2017-02-04 US US16/075,080 patent/US10780091B2/en active Active
- 2017-02-04 DK DK17747003.6T patent/DK3412671T3/da active
- 2017-02-04 UA UAA201809085A patent/UA123781C2/uk unknown
- 2017-02-04 CA CA3013682A patent/CA3013682C/en active Active
- 2017-02-06 AR ARP170100296A patent/AR107547A1/es active IP Right Grant
-
2018
- 2018-08-01 ZA ZA2018/05185A patent/ZA201805185B/en unknown
- 2018-08-02 IL IL260965A patent/IL260965B/en unknown
- 2018-08-03 CL CL2018002089A patent/CL2018002089A1/es unknown
-
2020
- 2020-08-12 US US16/991,639 patent/US20200368241A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107547A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CL2019003610A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| CO2020007018A2 (es) | Proceso para preparar tapinarof | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CU20160149A7 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| CO2019007834A2 (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| MX2021002382A (es) | Sales y formas cristalinas de modulador alosterico positivo gabaa. | |
| CL2018002101A1 (es) | Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CL2020000376A1 (es) | Compuesto pentacíclico. | |
| CR20160494A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| MX2019011931A (es) | Formas cristalinas de (s)-afoxolaner. | |
| CO2018002364A2 (es) | Una novedosa forma de isoxadifeno-etilo, un proceso para su preparación y uso de la misma | |
| BR112016023767A2 (pt) | forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações | |
| MX2020003832A (es) | Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. | |
| CL2018002149A1 (es) | Proceso. | |
| CO2017010725A2 (es) | N-[3-[(4as,5s,7as)-2-amino-5-(1,1-difluoroetil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-ciano-2-picolamida, su sal metanosulfonato y una forma cristalina hemihidrato de la sal 4-metilbencenosulfonato del mismo, composiciones que los contienen y procedimientos para su elaboración | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| MX379825B (es) | Nuevas formas cristalinas de la sal de monosodio del foramsulfuron. | |
| MX2013007504A (es) | Composiciones y metodos de uso de formas cristalinas de analogos de wortmanina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |